Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
64.95
+9.75 (17.66%)
At close: May 20, 2026, 4:00 PM EDT
65.44
+0.49 (0.75%)
After-hours: May 20, 2026, 4:23 PM EDT
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$681,135
Market Cap
435.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Lyell Immunopharma | 161 |
| Enanta Pharmaceuticals | 120 |
| C4 Therapeutics | 104 |
| Verastem | 102 |
| InflaRx | 65 |
| Lexeo Therapeutics | 59 |
| Zura Bio | 40 |
MNPR News
- 23 hours ago - Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - GlobeNewsWire
- 6 days ago - Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 days ago - Monopar Therapeutics Quarterly report: Q1 2026 - Filings
- 6 days ago - Monopar Therapeutics Earnings release: Q1 2026 - Filings
- 20 days ago - Monopar Therapeutics Proxy statement: Proxy filing - Filings
- 20 days ago - Monopar Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840 - TheFly
- 4 weeks ago - Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - GlobeNewsWire